Novartis is conducting a comprehensive product quality review of Beovu, a treatment for wet age-related macular degeneration, after the American Society of Retina Specialists shared an update with its membership on possible side effects of the therapy.
According to a Novartis statement to Healio/OSN on Feb. 25, the ASRS sent an update on Beovu (brolucizumab-dbll) to its members about reports of 14 cases of vasculitis in patients treated with the drug since its approval by the FDA in October 2019.
As of Feb. 28, the company’s global safety organization is (Read more...)
Uncategorized